
TFX • NYSE
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold TFX in your mock portfolio yet.
Teleflex’s negative EPS and resulting negative PE ratio point to current unprofitability despite its status as an established medical technology company. While revenue is not provided, the earnings profile suggests margin or one-time charge pressures that weigh on equity valuation. Until profitability normalizes, the stock is likely to trade at a discount to historical and peer multiples.
Teleflex’s stock at $103.00 is trading well below its 200-day moving average of $122.19, indicating a sustained downtrend. An RSI of 31.18 signals the shares are approaching oversold territory, suggesting selling pressure has been persistent, though a short-term bounce is possible. Overall, the technical setup leans bearish with some potential for near-term mean reversion rather than a confirmed trend reversal.
Teleflex’s alternative data picture is mixed but not strongly negative. Monthly web traffic of about 191,612 visitors and 154 open roles suggest an active commercial footprint and ongoing investment in growth and operations. A sizable LinkedIn following indicates solid professional brand presence, but none of these signals clearly offset the concerns raised by weak earnings and technical pressure.
Teleflex’s current setup skews bearish, with negative EPS and a negative PE ratio pointing to earnings challenges and the stock trading well below its 200-day moving average. While hiring activity, web traffic, and professional social presence indicate an operationally active company, they do not yet counterbalance the weak profitability and downtrending technicals. Until there is clearer evidence of earnings recovery or a sustained technical base, the risk-reward profile appears tilted to the downside.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: